ofloxacin has been researched along with ulifloxacin in 13 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 5 (38.46) | 18.2507 |
2000's | 7 (53.85) | 29.6817 |
2010's | 1 (7.69) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kazuno, K; Kise, M; Kitano, M; Matsuda, M; Matsuoka, M; Ozaki, M; Segawa, J; Shirahase, I; Tomii, Y | 1 |
Kimura, K; Kise, M; Kitano, M; Matsuda, M; Nishino, T; Otsuki, M; Ozaki, M; Segawa, J; Shibata, K; Tomii, Y | 1 |
Mitsuhashi, S; Yoshida, T | 1 |
Saito, H; Sato, K; Tomioka, H | 1 |
Honmura, T; Komori, K; Matsuda, M; Nishimura, I; Nishino, T; Ozaki, M; Tomii, Y; Yamaguchi, R | 1 |
Eda, T; Hosaka, M; Hoshino, K; Inoue, M; Kaieda, S; Kitasato, H; Kuga, A; Okamoto, R; Sato, Y; Seto, I | 1 |
Araake, M; Hara, T; Nishino, T; Watabe, H | 1 |
Araake, M; Hara, T; Nishino, T; Shimizu, M; Tabata, M; Watabe, H | 1 |
Araake, M; Maebashi, K; Tani, M; Watabe, H | 1 |
Hikida, M; Kariyama, R; Kato, Y; Kumon, H; Mikuniya, T; Monden, K | 1 |
Jin, L; Shen, B; Wang, X; Zhao, H | 1 |
Cochetti, I; Minardi, D; Mingoia, M; Montanari, MP; Muzzonigro, G; Tili, E; Varaldo, PE | 1 |
Di Maggio, T; Mantengoli, E; Montagnani, F; Pallecchi, L; Pollini, S; Riccobono, E; Rossolini, GM | 1 |
13 other study(ies) available for ofloxacin and ulifloxacin
Article | Year |
---|---|
Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Carboxylic Acids; Escherichia coli Infections; Fluoroquinolones; Male; Mice; Microbial Sensitivity Tests; Pseudomonas Infections; Quinolones; Structure-Activity Relationship | 1992 |
In vivo evaluation of NM441, a new thiazeto-quinoline derivative.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dogs; Drug Evaluation, Preclinical; Enoxacin; Female; Fluoroquinolones; Male; Mice; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Prodrugs; Quinolones; Respiratory Tract Infections; Streptococcal Infections; Urinary Tract Infections | 1991 |
Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone.
Topics: Anti-Infective Agents; Bacteria; Ciprofloxacin; Dioxolanes; Enoxacin; Fluoroquinolones; Microbial Sensitivity Tests; Mutation; Naphthyridines; Ofloxacin; Piperazines; Quinolones; Topoisomerase II Inhibitors | 1993 |
[In vitro antimycobacterial activity of a new quinolone, NM394].
Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium; Mycobacterium tuberculosis; Ofloxacin; Piperazines; Quinolones | 1993 |
Uptake and intracellular activity of NM394, a new quinolone, in human polymorphonuclear leukocytes.
Topics: Amino Acids; Anti-Infective Agents; Antimetabolites; Ciprofloxacin; Fluoroquinolones; Humans; Hydrogen-Ion Concentration; In Vitro Techniques; Neutrophils; Nucleic Acids; Ofloxacin; Phagocytosis; Piperazines; Pseudomonas aeruginosa; Quinolones | 1996 |
[In vitro antibacterial activity of prulifloxacin, a new oral quinolone, and comparative susceptibility rate at clinical breakpoint MIC].
Topics: Anti-Infective Agents; Bacteria; Dioxolanes; Drug Resistance, Microbial; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Piperazines; Quinolones; Respiratory Tract Infections; Sepsis | 2000 |
[In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dosage Forms; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fleroxacin; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Naphthyridines; Ofloxacin; Piperazines; Prodrugs; Quinolones | 2002 |
[In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Gatifloxacin; Levofloxacin; Ofloxacin; Piperazines; Prodrugs; Pseudomonas aeruginosa; Quinolones; Staphylococcus aureus; Time Factors | 2002 |
[Inhibitory activity of NM394, the active form of prodrug prulifloxacin against type II topoisomerase from Pseudomonas aeruginosa].
Topics: Anti-Infective Agents; Ciprofloxacin; Dioxolanes; DNA Topoisomerase IV; Dose-Response Relationship, Drug; Fluoroquinolones; Gatifloxacin; Levofloxacin; Ofloxacin; Piperazines; Prodrugs; Pseudomonas aeruginosa; Quinolones; Topoisomerase II Inhibitors | 2002 |
Synergistic effect of fosfomycin and fluoroquinolones against Pseudomonas aeruginosa growing in a biofilm.
Topics: Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Drug Synergism; Fluoroquinolones; Fosfomycin; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Pseudomonas aeruginosa; Quinolones | 2005 |
Determination of ulifloxacin by terbium-sensitized fluorescence with second-order scattering and its applications.
Topics: Anti-Bacterial Agents; Fluoroquinolones; Humans; Indicators and Reagents; Luminescence; Norfloxacin; Ofloxacin; Piperazines; Quinolones; Scattering, Radiation; Spectrometry, Fluorescence; Terbium | 2007 |
Effects of fluoroquinolones on bacterial adhesion and on preformed biofilm of strains isolated from urinary double J stents.
Topics: Anti-Infective Agents, Urinary; Bacterial Adhesion; Biofilms; Dose-Response Relationship, Drug; Enterococcus; Escherichia coli; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Pseudomonas aeruginosa; Quinolones; Staphylococcus; Stenotrophomonas maltophilia; Stents; Ureteral Calculi | 2008 |
Antipneumococcal activity of ulifloxacin compared to levofloxacin and ciprofloxacin.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Disk Diffusion Antimicrobial Tests; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Italy; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Pneumococcal Infections; Streptococcus pneumoniae | 2011 |